Growth Metrics

Biogen (BIIB) Total Non-Current Liabilities (2016 - 2025)

Biogen has reported Total Non-Current Liabilities over the past 17 years, most recently at $10.4 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $10.4 billion for Q4 2025, down 1.57% from a year ago — trailing twelve months through Dec 2025 was $10.4 billion (down 1.57% YoY), and the annual figure for FY2025 was $10.4 billion, down 1.57%.
  • Total Non-Current Liabilities for Q4 2025 was $10.4 billion at Biogen, up from $10.2 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for BIIB hit a ceiling of $13.0 billion in Q3 2023 and a floor of $9.9 billion in Q1 2023.
  • Median Total Non-Current Liabilities over the past 5 years was $10.7 billion (2022), compared with a mean of $10.9 billion.
  • Peak annual rise in Total Non-Current Liabilities hit 19.07% in 2023, while the deepest fall reached 17.68% in 2023.
  • Biogen's Total Non-Current Liabilities stood at $11.6 billion in 2021, then fell by 11.86% to $10.2 billion in 2022, then rose by 10.2% to $11.3 billion in 2023, then dropped by 5.89% to $10.6 billion in 2024, then fell by 1.57% to $10.4 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $10.4 billion (Q4 2025), $10.2 billion (Q3 2025), and $9.9 billion (Q2 2025) per Business Quant data.